Generic molecule: lucinactant
Company: Discovery Laboratories
Approval date: March 6
The scoop: It was a long, hard haul for the specialty drug company to get this one approved. The FDA several times asked the company for more data. After a rejection in 2009, when cash and patience were running short, the Discovery board tossed Robert Capetola, its CEO since the company's founding 13 years earlier, and for awhile replaced him with board Chairman Thomas Amick, a Johnson & Johnson ($JNJ) alum.